Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 33,093 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

NCT06441318
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Placebo, Moxifloxacin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

NCT01817790
View directory record Official record
Conditions
Allergic Rhinitis, Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
626 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT03977155
View directory record Official record
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
BOS-589, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 24, 2026, 5:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Nabilone in Cannabis Users With PTSD

NCT03251326
View directory record Official record
Conditions
Cannabis, Post Traumatic Stress Disorder
Interventions
Nabilone, Cannabis, Propranolol, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03653026
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
114
States / cities
Mobile, Alabama • Sun City, Arizona • Tempe, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 24, 2026, 5:22 AM EDT
Withdrawn Phase 2 Interventional

ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

NCT04256148
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
ALXN1830, Placebo
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients

NCT00002248
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Cryptosporidium Immune Whey Protein Concentrate (Bovine)
Drug
Lead sponsor
Univax Biologics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction

NCT01056926
View directory record Official record
Conditions
Smoking
Interventions
Quit smoking, Nicotine patch, Placebo Patch
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 24, 2026, 5:22 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)

NCT01272778
View directory record Official record
Conditions
Healthy Subjects
Interventions
Lorazepam, Placebo
Drug
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Oct 24, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

NCT04084678
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Aurora, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 24, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

NCT02766478
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genistein, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 4 Interventional

A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia

NCT00455715
View directory record Official record
Conditions
Schizophrenia
Interventions
Sildenafil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 24, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

NCT00610935
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
96
States / cities
Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

NCT06179108
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
25
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 24, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional

Efficacy and Safety of Coenzyme Q10 in the Treatment of Statin-Associated Myalgia

NCT00590408
View directory record Official record
Conditions
Statin-associated Myalgia
Interventions
coenzyme Q10, matching placebo
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

NCT05620576
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
LY3857210, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
28
States / cities
Chandler, Arizona • Phoenix, Arizona • Riverside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Not applicable Interventional

Microcurrent Treatment for Chronic Debilitating Pain

NCT04011176
View directory record Official record
Conditions
Pain, Opioid Use
Interventions
Standard treatment + placebo, Standard treatment + Microcurrent Therapy
Procedure
Lead sponsor
Paul Crawford
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease

NCT03819517
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Resveratrol, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 24, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

Management Of Pain After Cesarean Trial

NCT03929640
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use
Interventions
Acetaminophen, Placebo, Ibuprofen
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT02456740
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Phoenix, Arizona • Anaheim, California • Encino, California + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

NCT04882878
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Nipocalimab, Standard-of-care treatment
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Los Alamitos, California • Rancho Mirage, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

NCT01769755
View directory record Official record
Conditions
Crohns Disease
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 24, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis

NCT01565655
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
peficitinib, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
19
States / cities
Birmingham, Alabama • La Jolla, California • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 24, 2026, 5:22 AM EDT